Intensive insulin therapy

Global Market Analysis on Diabetes Care Devices with Forecast Models for Insulin Pens - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 22, 2020
Diabetes, Health, Medical devices, Eli Lilly and Company, Medicine, Endocrine system, Endocrinology, Insulin pen, Insulin pump, Insulin, Syringe, Insulin analog, Intensive insulin therapy

The "Insulin Pens (Diabetes Care Devices) - Global Market Analysis and Forecast Model" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Insulin Pens (Diabetes Care Devices) - Global Market Analysis and Forecast Model" report has been added to ResearchAndMarkets.com's offering.
  • Insulin can be delivered by syringes, insulin pumps, and insulin pens.
  • Insulin pens dominate the global insulin delivery market due to their easy usage, increased patient satisfaction, and cost-effectiveness.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Insulin Pens market in the future.

Hygieia creates first technology to automate dose adjustment for all common insulin regimens

Retrieved on: 
Thursday, April 9, 2020
Eli Lilly and Company, Medicine, Endocrine system, Clinical medicine, Insulin, Insulin pump, Intensive insulin therapy

Using artificial intelligence and patented technology, Hygieia's d-Nav insulin management program automatically determines how much insulin a patient needs at the time of injection.

Key Points: 
  • Using artificial intelligence and patented technology, Hygieia's d-Nav insulin management program automatically determines how much insulin a patient needs at the time of injection.
  • That creates a barrier to care, because people's insulin needs are dynamic and often require much more frequent titration.
  • The d-Nav program uses a handheld device and patented technology to measure glucose, identify glucose patterns and automatically calculate the next individualized insulin dose.
  • Users simply insert their test strip into a handheld device and d-Nav analyzes the information and provides a recommended insulin dose.

InPen Adds Fixed Dose and Meal Estimation Options

Retrieved on: 
Wednesday, April 8, 2020
Endocrine system, Medicine, Organ systems, Eli Lilly and Company, Diabetes, RTT, Peptide hormones, Recombinant proteins, Insulin, Diabetes management, Type 1 diabetes, Intensive insulin therapy

The new InPen app now provides an insulin therapy solution for people with Type 1 or Type 2 insulin-dependent diabetes by providing a fixed dose and meal estimation dose calculator for those who administer insulin based on fixed meal amounts or the relative size of their planned meals.

Key Points: 
  • The new InPen app now provides an insulin therapy solution for people with Type 1 or Type 2 insulin-dependent diabetes by providing a fixed dose and meal estimation dose calculator for those who administer insulin based on fixed meal amounts or the relative size of their planned meals.
  • These new capabilities - available to healthcare providers and InPen users across the US today - position InPen to help the majority of patients using multiple daily injections, regardless of their personal insulin regimen.
  • Also in this release is the newest version of the InSights by InPen report which offers a revolutionary new view of insulin therapy exclusive to InPen patients and prescribers.
  • The InPen system, which includes a smart pen and diabetes management app, is available in the US by prescription only.

Global Insulin Pens, Syringes, Pumps And Injectors Market To Grow At A CAGR Of 8.71% During 2019-2023

Retrieved on: 
Friday, April 3, 2020
Medicine, Eli Lilly and Company, Endocrine system, Endocrinology, Insulin pump, Syringe, Insulin, Minimed Paradigm, Intensive insulin therapy

The tubeless insulin pumps can be controlled from a wireless handheld device and enables delivery of insulin discretion.

Key Points: 
  • The tubeless insulin pumps can be controlled from a wireless handheld device and enables delivery of insulin discretion.
  • The tubeless insulin pumps provide consistent, round the clock, uninterrupted insulin delivery, and helps users to avoid taking four to five insulin injections per day.
  • Request A Sample Of The Insulin Pens, Syringes, Pumps And Injectors Market @ https://www.thebusinessresearchcompany.com/sample.aspx?id=2461&type=smp
    Insulin pens, syringes, pumps and injectors are used to administer insulin to control blood glucose levels in diabetic patients.
  • The insulin pens, syringes, pumps and injectors market is segmented by type of devices into pens, injectors and pumps, and syringes.

FDA Clears InPen Diabetes Management System for Fixed Dosing and Meal Estimation

Retrieved on: 
Friday, February 28, 2020
Eli Lilly and Company, Endocrine system, Medicine, Endocrinology, Diabetes, RTT, Peptide hormones, Recombinant proteins, Diabetes management, Insulin, Type 1 diabetes, Intensive insulin therapy

Companion Medical today confirmed that it has received clearance from the FDA for its InPen bolus calculator for fixed dosing and meal estimation.

Key Points: 
  • Companion Medical today confirmed that it has received clearance from the FDA for its InPen bolus calculator for fixed dosing and meal estimation.
  • These new capabilities allow InPen to help the majority of patients using multiple daily injections, regardless of their personal insulin regimen.
  • "The biggest predictor of better control amongst people living with diabetes is the number of insulin doses per day.
  • The company's flagship product, InPen, is the first FDA-cleared smart insulin pen and mobile app-based diabetes management system providing people with diabetes and healthcare providers with essential data to optimize insulin regimens.

Roche presents RocheDiabetes InsulinStart, a new service for an easy start to insulin therapy

Retrieved on: 
Thursday, February 20, 2020
Organ systems, Endocrine system, Medicine, Eli Lilly and Company, RTT, Peptide hormones, Recombinant proteins, Insulin, Anti-diabetic medication, Diabetes, Type 1 diabetes, Intensive insulin therapy

-- RocheDiabetes InsulinStart is a service designed for people with type 2 diabetes to ease the transition from oral antidiabetics to a complementary long-acting insulin therapy.

Key Points: 
  • -- RocheDiabetes InsulinStart is a service designed for people with type 2 diabetes to ease the transition from oral antidiabetics to a complementary long-acting insulin therapy.
  • The start of this so-called Basal insulin-supported Oral Therapy (BOT) poses challenges for patients and healthcare professionals alike.
  • "RocheDiabetes InsulinStart responds to the needs of people who have to inject long-acting insulin once a day with an easy service that enables a successful start into the unfamiliar therapy.
  • Especially in these aspects, the RocheDiabetes InsulinStart service provides support facilitating a better response to the therapy needs of people with diabetes.

Smart Insulin Pens and Pumps Market Size Worth $6.3 Billion by 2026: Grand View Research, Inc.

Retrieved on: 
Tuesday, January 14, 2020
Eli Lilly and Company, Medicine, Endocrine system, Clinical medicine, Insulin pen, Insulin, Medtronic, Novo Nordisk, Insulin pump, Intensive insulin therapy

Self-injection devices with integrated connectivity have become an important element of the digital ecosystem.

Key Points: 
  • Self-injection devices with integrated connectivity have become an important element of the digital ecosystem.
  • Many key players are focusing on technological collaborations, which is expected to have a long-term positive impact on the market.
  • For instance, in September 2019, Medtronic collaborated with Novo Nordisk to integrate Novo future smart insulin pen dosage data with Medtronic CGM devices.
  • Grand View Research has segmented the global smart insulin pens and pumps market based on product type, end use, and region:
    Smart Insulin Pens and Pumps Product Type Outlook (Revenue, USD Million, 2015 - 2026)

Smart Insulin Pens and Pumps Market Size Worth $6.3 Billion by 2026: Grand View Research, Inc.

Retrieved on: 
Tuesday, January 14, 2020
Eli Lilly and Company, Medicine, Endocrine system, Clinical medicine, Insulin pen, Insulin, Medtronic, Novo Nordisk, Insulin pump, Intensive insulin therapy

Self-injection devices with integrated connectivity have become an important element of the digital ecosystem.

Key Points: 
  • Self-injection devices with integrated connectivity have become an important element of the digital ecosystem.
  • Many key players are focusing on technological collaborations, which is expected to have a long-term positive impact on the market.
  • For instance, in September 2019, Medtronic collaborated with Novo Nordisk to integrate Novo future smart insulin pen dosage data with Medtronic CGM devices.
  • Grand View Research has segmented the global smart insulin pens and pumps market based on product type, end use, and region:
    Smart Insulin Pens and Pumps Product Type Outlook (Revenue, USD Million, 2015 - 2026)

Global Insulin Pumps & Accessories Market Analysis with Forecasts to 2026 - Emergence of Smart Pumps, Market Expansion in Emerging Nations, Product Approvals

Retrieved on: 
Tuesday, December 24, 2019
Medicine, Eli Lilly and Company, Clinical medicine, Endocrine system, RTT, Peptide hormones, Recombinant proteins, Insulin pump, Insulin, Diabetes, Intensive insulin therapy

Increase in the prevalence of diabetes, technological advancements, adoption of insulin pumps over traditional methods and advantages of insulin pumps over the injections and pens are the factors driving the market growth.

Key Points: 
  • Increase in the prevalence of diabetes, technological advancements, adoption of insulin pumps over traditional methods and advantages of insulin pumps over the injections and pens are the factors driving the market growth.
  • The increasing trend for wireless insulin pumps, emergence of smart pumps and market expansion in emerging nations and product approvals are expected to offer potential opportunities.
  • However, various factors like, high cost, patient safety risks and medication errors associated with insulin pumps, lack of cyber-security in wireless insulin pumps limit the growth of insulin pumps & accessories global market.
  • Insulin pumps & accessories market is segmented on the basis of products, applications, end-users and geography
    The insulin pumps & accessories products market is segmented into insulin pumps, consumables, among them insulin pumps held the largest share of the market in 2019 and are expected to grow at a high single digit CAGR from 2019 to 2026.

Arecor Announces Positive Headline Results for the First Phase I Clinical Trial of AT247, a Novel Ultra Rapid Acting Formulation of Insulin

Retrieved on: 
Thursday, December 5, 2019
Eli Lilly and Company, Endocrine system, Hormones, Branches of biology, Peptide hormones, Recombinant proteins, RTT, Diabetes, Insulin, EudraCT, Insulin analog, Intensive insulin therapy

CAMBRIDGE, United Kingdom, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Arecor Limited (Arecor or the Company), the biopharmaceutical company advancing todays therapies to enable healthier lives, today announces positive headline results for the Phase I clinical trial of its ultra-rapid acting insulin product candidate, AT247.

Key Points: 
  • CAMBRIDGE, United Kingdom, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Arecor Limited (Arecor or the Company), the biopharmaceutical company advancing todays therapies to enable healthier lives, today announces positive headline results for the Phase I clinical trial of its ultra-rapid acting insulin product candidate, AT247.
  • AT247, an investigational novel meal-time insulin formulation, aims to significantly accelerate insulin absorption, post injection, to enable more effective management of blood glucose levels.
  • The double-blind, randomised, three-period cross over Phase I clinical study (EudraCT:2018-003934-34) compared the pharmacokinetic and pharmacodynamic profiles of AT247 to NovoRapid and Fiasp.
  • We look forward to reporting the full data from this Phase I study in due course.